New Zealand markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
572.36+2.99 (+0.53%)
At close: 4:00PM EDT
572.00 -0.36 (-0.06%)
After hours: 07:38PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 558.13B
Enterprise value 356.91B
Trailing P/E 9.78
Forward P/E 111.06
PEG ratio (5-yr expected) 10.96
Price/sales (ttm)4.92
Price/book (mrq)3.84
Enterprise value/revenue 34.60
Enterprise value/EBITDA 77.53

Trading information

Stock price history

Beta (5Y monthly) 0.21
52-week change 3-2.28%
S&P500 52-week change 333.64%
52-week high 3686.62
52-week low 3441.00
50-day moving average 3602.42
200-day moving average 3564.27

Share statistics

Avg vol (3-month) 3781.19k
Avg vol (10-day) 3844.49k
Shares outstanding 5105.11M
Implied shares outstanding 6106.95M
Float 899.26M
% held by insiders 12.75%
% held by institutions 186.32%
Shares short (29 Sep 2021) 41.8M
Short ratio (29 Sep 2021) 42.53
Short % of float (29 Sep 2021) 42.02%
Short % of shares outstanding (29 Sep 2021) 41.68%
Shares short (prior month 30 Aug 2021) 41.36M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021

Profitability

Profit margin 50.88%
Operating margin (ttm)52.46%

Management effectiveness

Return on assets (ttm)22.27%
Return on equity (ttm)51.32%

Income statement

Revenue (ttm)12.2B
Revenue per share (ttm)115.78
Quarterly revenue growth (yoy)163.20%
Gross profit (ttm)4.46B
EBITDA 6.66B
Net income avi to common (ttm)6.21B
Diluted EPS (ttm)55.38
Quarterly earnings growth (yoy)245.40%

Balance sheet

Total cash (mrq)3.91B
Total cash per share (mrq)37.62
Total debt (mrq)2.7B
Total debt/equity (mrq)17.83
Current ratio (mrq)3.57
Book value per share (mrq)145.83

Cash flow statement

Operating cash flow (ttm)2.27B
Levered free cash flow (ttm)236.12M